Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 12, 2019
- Accepted for publication November 11, 2019
- Published online May 1, 2020.
Article Versions
- previous version (December 5, 2019 - 10:37).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- 1Nuclear Medicine, S. Orsola Hospital, University of Bologna, Bologna, Italy
- 2Department of Urology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany
- 3German Cancer Consortium, Heidelberg, Germany; and
- 4Department of Nuclear Medicine, Essen University Hospital, University of Duisburg-Essen, Essen, Germany
- For correspondence or reprints contact: Ken Herrmann, Department of Nuclear Medicine, Universitätsklinikum Essen, Hufelandstrasse 55, 45147 Essen, Germany. E-mail: ken.herrmann{at}uk-essen.de
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
- Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T
- The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
- Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
- PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer
- Prognostic Role of 68Ga-PSMA11 PET-Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy
- Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
- The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
- Repeatability of 68Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor Volume
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging
- Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
- Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
- Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
- PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study